Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1

New England Journal of Medicine

Volumn 348, Issue 15, 2003, Pages 1442-1448

  Siddiqui, Asra ^a   Kerb, Reinhold ^e   Weale, Michael E ^c,d   Brinkmann, Ulrich ^e   Smith, Alice ^b   Goldstein, David B ^b,d   Wood, Nicholas W ^a,d   Sisodiya, Sanjay M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Genostics Ltd   (United Kingdom)

^d National Neurological Institute   (Singapore)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTICONVULSIVE AGENT; GLYCOPROTEIN P;

ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; EPILEPSY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSOCIAL DISORDER;

CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE; EPILEPSY; GENE FREQUENCY; GENES, MDR; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 0037431040     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021986     Document Type: Article

References (32)

1. Casetta I, Granieri E, Monetti VC, et al. Early predictors of intractability in childhood epilepsy: a community-based case-control study in Copparo, Italy. Acta Neurol Scand 1999;99:329-33.
2. Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001;70:240-3.
3. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48:833-41. [Errata, Ann Neurol 2001; 49:547, 50:830.]
4. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40:Suppl:S3-S8.
5. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.
6. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
7. Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999;10:3437-41.
8. Sisodiya SM, Lin W-R, Squier MV, Thom M. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357:42-3.
9. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
10. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999;21:731-4.
11. Dombrowski SM, Desai SY, Marroni M, etal. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-6.
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
13. Roy-Engel AM, Carroll ML, Vogel E, et al. Alu insertion polymorphisms for the study of human genomic diversity. Genetics 2001;159:279-90.
14. Carroll ML, Roy-Engel AM, Nguyen SV, et al. Large-scale analysis of the Alu Ya5 and Yb8 subfamilies and their contribution to human genomic diversity. J Mol Biol 2001;311:17-40.
15. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-74.
16. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43.
17. Reich DE, Goldstein DB. Detecting association in a case-control study while correcting for population stratification. Genet Epidemiol 2001;20:4-16.
18. Weir BS. Genetic-data analysis II: methods for discrete population genetic data. Sunderland, Mass.: Sinauer, 1996.
19. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
20. Llorente L, Richaud-Patin Y, Diaz-Borjon A, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. I. Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000;67:30-9.
21. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-88.
22. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-8.
23. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-6.
24. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-34.
25. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
26. Goldstein DB. Islands of linkage disequilibrium. Nat Genet 2001;29:109-11.
27. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet 2001;29:229-32.
28. Shapiro AB, Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl 1998;643:227-34.
29. Schinkel AH. P-glycoprotein, a gate-keeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94.
30. Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-10.
31. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-60.
32. Tai HL. Technology evaluation: valspodar, Novartis AG. Curr Opin Mol Ther 2000;2:459-67.